Tuber yield and processing traits of potato advanced selections

World potato production continuously requires new cultivars to satisfy farmers’ and consumers’ demand. Tuber yield and quality are some of the main potato breeding targets. In this study, 27 advanced potato clones from 7 hybrid families were evaluated for yield, tuber specific gravity and chipping ability. Variability in tuber yield was found between families as well as between clones. Forty-eight percent of clones showed higher productivity compared to the best control (Agria, 1.1 Kg). Families displayed significant differences also in terms of tubers specific gravity, with about 70% of clones with a score higher than 1.080, which was considered the minimum acceptable value for processing. Chipping ability was evaluated at harvesting time and after cold storage with and without reconditioning. The majority of studied clones showed a good chipping ability score (<4.5) at harvest; five samples chipped well after cold storage with reconditioning, while good chippers were not identified after cold storage without reconditioning. The use of an arbitrary index calculated for each clone is proposed to assist the selection of materials with a good trait combination

Hybrid topoisomerase i and HDAC inhibitors as dual action anticancer agents

Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivatives in combination therapies. To exploit this synergy, new hybrid molecules targeting simultaneously topoisomerase I and HDAC were designed. In particular, a selected multivalent agent containing a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection

Ebola virus (EBOV) causes acute hemorrhagic fever in humans and non-human primates with mortality rates up to 90%. So far there are no effective treatments available. This study evaluates the protective efficacy of 8 monoclonal antibodies (MAbs) against Ebola glycoprotein in mice and guinea pigs. Immunocompetent mice or guinea pigs were given MAbs i.p. in various doses individually or as pools of 3–4 MAbs to test their protection against a lethal challenge with mouse- or guinea pig-adapted EBOV. Each of the 8 MAbs (100 µg) protected mice from a lethal EBOV challenge when administered 1 day before or after challenge. Seven MAbs were effective 2 days post-infection (dpi), with 1 MAb demonstrating partial protection 3 dpi. In the guinea pigs each MAb showed partial protection at 1 dpi, however the mean time to death was significantly prolonged compared to the control group. Moreover, treatment with pools of 3–4 MAbs completely protected the majority of animals, while administration at 2–3 dpi achieved 50–100% protection. This data suggests that the MAbs generated are capable of protecting both animal species against lethal Ebola virus challenge. These results indicate that MAbs particularly when used as an oligoclonal set are a potential therapeutic for post-exposure treatment of EBOV infection